SCHEMBL19965839

SCHEMBL19965839

CCOC(=O)N1CCC(N2CCC3(CC2)OC(=O)NC3CC)CC1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.47
TDP1 Q9NUW8 1/20 0.47
CHRM1 P11229 3/20 0.47
GAA P10253 3/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
ALOX12 P18054 1/20 0.45
MAPK1 P28482 1/20 0.45
CHRM2 P08172 2/20 0.44
CHRM4 P08173 1/20 0.44
CHRM5 P08912 1/20 0.44
CHRM3 P20309 1/20 0.44
L3MBTL1 Q9Y468 2/20 0.42
POLB P06746 1/20 0.41
ALDH1A1 P00352 3/20 0.41
KDM4E B2RXH2 2/20 0.41
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
KCNH2 Q12809 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18075934 0.86 CHRM4 (0.39) TP53TDP1CHRM1GAASMN1; SMN2
SCHEMBL18075901 0.86 CHRM4 (0.41) TP53TDP1CHRM1GAASMN1; SMN2
SCHEMBL17101492 0.85 CHRM1 (0.40) CHRM1CHRM2CHRM4CHRM5
SCHEMBL18075884 0.84 CHRM4 (0.46) TP53TDP1CHRM1GAASMN1; SMN2
SCHEMBL22472893 0.83 CHRM1 (0.31) TP53CHRM1MAPK1L3MBTL1POLB
SCHEMBL21597923 0.81 CHRM1 (0.33) CHRM1CHRM2CHRM4CHRM5POLB
SCHEMBL23316171 0.81 LMNA (0.31) CHRM1MAPK1POLBKDM4E
SCHEMBL18075961 0.79 CHRM4 (0.37) TP53CHRM1MAPK1CHRM2CHRM4
SCHEMBL19965818 0.79 CHRM1 (0.48) TP53TDP1CHRM1GAASMN1; SMN2
SCHEMBL17101279 0.78 TP53 (0.31) TP53TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3271358-B1 SPIROCYCLIC COMPOUNDS AS AGONISTS OF THE MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR HEPTARES THERAPEUTICS LTD (GB) 2020-11-18 EP disclosed
US-10167284-B2 Spirocyclic compounds as agonists of the muscarinic M1 receptor and/or M4 receptor HEPTARES THERAPEUTICS LIMITED (GB) 2019-01-01 US disclosed
US-20180072727-A1 SPIROCYCLIC COMPOUNDS AS AGONISTS OF THE MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR NXERA PHARMA UK LIMITED (GB) 2018-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10167284-B2 Spirocyclic compounds as agonists of the muscarinic M1 receptor and/or M4 receptor CHRM1, CHRM2, CHRM4 TP53 2027/4885TDP1 4028/4885CHRM1 1/4885
US-20180072727-A1 SPIROCYCLIC COMPOUNDS AS AGONISTS OF THE MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR CHRM1, CHRM2, CHRM4 TP53 2190/4885TDP1 3925/4885CHRM1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.